[Japanese practice of comprehensive treatment for peritoneal metastasis of gastric cancer].

Q3 Medicine 中华胃肠外科杂志 Pub Date : 2023-10-25 DOI:10.3760/cma.j.cn441530-20230706-00238

Y Liu, C L Yutaka, L X Toshiyuki, Y Li

{"title":"[Japanese practice of comprehensive treatment for peritoneal metastasis of gastric cancer].","authors":"Y Liu, C L Yutaka, L X Toshiyuki, Y Li","doi":"10.3760/cma.j.cn441530-20230706-00238","DOIUrl":null,"url":null,"abstract":"<p><p>Patients with peritoneal metastasis (PM) from gastric cancer (GC) have a poor prognosis. Surgery or systemic treatment alone hardly improves the prognosis and overall survival (OS). A newly developed comprehensive treatment involving a combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has been used to treat patients with PM from GC. The Peritoneal Dissemination Center of Kishiwada Tokushukai Hospital in Japan has been committed to treating patients with PM from GC. Selected patients undergo laparoscopic hyperthermic intraperitoneal chemotherapy (LHIPEC), preoperative intraperitoneal (IP) chemotherapy, and systemic chemotherapy that includes intravenous and oral chemotherapy prior to surgery. CRS plus HIPEC is then performed to achieve complete cytoreduction. Postoperative IP chemotherapy or systemic chemotherapy is also administered to nearly all patients. The results demonstrate that comprehensive treatment, including neoadjuvant chemotherapy and CRS plus HIPEC, can significantly improve the prognosis and OS of selected patients with PM from GC.</p>","PeriodicalId":23959,"journal":{"name":"中华胃肠外科杂志","volume":"26 10","pages":"992-996"},"PeriodicalIF":0.0000,"publicationDate":"2023-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华胃肠外科杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/cma.j.cn441530-20230706-00238","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Patients with peritoneal metastasis (PM) from gastric cancer (GC) have a poor prognosis. Surgery or systemic treatment alone hardly improves the prognosis and overall survival (OS). A newly developed comprehensive treatment involving a combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has been used to treat patients with PM from GC. The Peritoneal Dissemination Center of Kishiwada Tokushukai Hospital in Japan has been committed to treating patients with PM from GC. Selected patients undergo laparoscopic hyperthermic intraperitoneal chemotherapy (LHIPEC), preoperative intraperitoneal (IP) chemotherapy, and systemic chemotherapy that includes intravenous and oral chemotherapy prior to surgery. CRS plus HIPEC is then performed to achieve complete cytoreduction. Postoperative IP chemotherapy or systemic chemotherapy is also administered to nearly all patients. The results demonstrate that comprehensive treatment, including neoadjuvant chemotherapy and CRS plus HIPEC, can significantly improve the prognosis and OS of selected patients with PM from GC.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

[日本综合治疗癌症腹膜转移的实践]。

癌症腹膜转移（PM）患者预后不良。单独的手术或全身治疗很难改善预后和总生存率（OS）。一种新开发的综合治疗方法，包括细胞减灭术（CRS）和腹腔内高温化疗（HIPEC）相结合，已用于治疗GC PM患者。日本Kishiwada Tokushukai医院腹膜传播中心一直致力于治疗GC PM患者。选定的患者在手术前接受腹腔镜腹膜内热疗化疗（LHIPEC）、术前腹膜内化疗（IP）和全身化疗，包括静脉和口服化疗。然后进行CRS加HIPEC以实现完全的细胞减少。术后IP化疗或全身化疗也适用于几乎所有患者。结果表明，综合治疗，包括新辅助化疗和CRS加HIPEC，可以显著改善GC中选定的PM患者的预后和OS。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊